Axe Compute Inc. annual report, FY2014

Business context and reporting period

The supplied filing is Skyline Medical Inc.’s Form 10-K for the fiscal year ended December 31, 2014—not a filing for Axe Compute Inc. or a standalone 2014 fourth quarter. Skyline develops and sells the STREAMWAY surgical-fluid management system and related disposable kits. The company reported 44 systems sold in 2014 versus 21 in 2013; more than 79 systems had been sold to date. Share and per-share amounts reflect a 1-for-75 reverse split effective October 24, 2014.

Financial performance and position

At December 31, 2014, cash was $16,384; current assets were $631,315 and current liabilities were $6,203,321. Total liabilities were $6,417,204, compared with total assets of $900,977, and stockholders’ deficit was $5,516,227. Accounts payable were $2,194,518 and accrued expenses were $3,280,262 (current and long-term combined). The filing separately states that approximately $6.417 million of debts, liabilities and cash obligations were past due or due during 2015. The company reported no outstanding bank debt or secured indebtedness.

Changes versus prior year

Revenue more than doubled, while cost of sales rose with volume and gross margin improved slightly. Net loss narrowed by about $2.6 million, principally as general and administrative expense fell from $7.53 million to $4.88 million, including lower stock-based and investor compensation. Sales and marketing expense increased to $1.18 million from $579,000, partly reflecting additional regional sales staff; research and development spending was approximately $394,000 versus $235,000. Operating cash use improved by about $484,000, largely because accounts payable and accrued expenses increased. Year-end cash nevertheless fell to $16,384 from $101,953.

Outlook, risks and unusual items

• Management anticipated continued net losses at least through the first two quarters of 2015 and reported ongoing operating cash outflows of approximately $250,000 per month. The company said it needed additional financing; a proposed public offering filed in September 2014 had not been completed.
• The independent auditor’s report raises substantial doubt about the company’s ability to continue as a going concern. The financial statements assume continued operations and do not include adjustments that might result if the company cannot continue.
• Convertible notes issued in 2014 carried 12% annual interest, were due July 23, 2015, and had variable-price conversion provisions. The filing states that $1.131 million of convertible-note principal was due on that date if not converted or redeemed. Conversion and warrant terms create potential dilution; the filing also describes preferred-stock rights and additional warrant issuances.
• Skyline agreed to a $500,000 settlement of litigation, payable in installments through April 25, 2015. The settlement extinguished plaintiffs’ prior royalty claims and affirmed Skyline’s rights to relevant patent assignments. The company reported $500,000 in settlement costs in 2014.
• Key business risks include limited adoption and operating history, stronger and better-funded competitors, dependence on external financing, possible supplier or creditor actions, regulatory requirements, intellectual-property risks and a thinly traded OTCQB stock. The company also disclosed potential claims relating to historical shareholder preemptive rights and significant control by affiliated holders.
• The filing describes the product’s intended safety and cost benefits and plans to expand sales, but provides no quantified revenue or profitability guidance. These benefits and planned growth are not assured.

Important facts for investors to verify

• Confirm the filing identity: the document names Skyline Medical Inc., whereas the request metadata names Axe Compute Inc.
• Review the complete audited statements and notes for debt maturities, accrued obligations, financing terms, preferred-stock rights and potential dilution; reconcile the disclosed $1.131 million note principal with the balance-sheet presentation of short-term notes payable.
• Assess whether subsequent financing was sufficient to address the disclosed cash burn and near-term obligations, and whether the pending public offering proceeded.
• Verify the sales trajectory, installed systems, repeat disposable-kit revenue and customer conversion from trials to paid purchases.
• Check share-count and reverse-split disclosures against the original filing: the cover text contains an apparent “2104” date typo for the October 2014 reverse split, and share counts differ by stated measurement date.